Ftse Mib
33.645,43
-0,27%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
62.455,70
5,64%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Monte Rosa Therapeutics Inc (GLUE) Monte Rosa Therapeutics Inc (GLUE) Notizie

Monte Rosa Therapeutics Inc

GLUE
5,65
0,05 (0,89%)
Dopo l'orario di negoziazione
Ultimo aggiornamento: 22:02:01
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
02/5/202422:01GLOBEMonte Rosa Therapeutics Announces the Departure of Owen..
14/3/202412:00GLOBEMonte Rosa Therapeutics Announces Fourth Quarter and Full..
11/3/202412:00GLOBEMonte Rosa Therapeutics Announces Initiation of IND Enabling..
31/1/202413:00GLOBEMonte Rosa Therapeutics to Participate in Upcoming Investor..
08/1/202413:47EDGAR2Form 8-K - Current report
08/1/202413:15GLOBEMonte Rosa Therapeutics Provides Corporate Update and Key..
04/1/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202413:00GLOBEMonte Rosa Therapeutics to Present at the 42nd Annual J.P...
21/11/202313:00GLOBEMonte Rosa Therapeutics to Present at Piper Sandler..
09/11/202313:27EDGAR2Form 8-K - Current report
09/11/202313:00GLOBEMonte Rosa Therapeutics Announces Third Quarter 2023..
07/11/202316:00GLOBEMonte Rosa Therapeutics Presents Preclinical Data at ACR..
27/10/202313:00GLOBEMonte Rosa Therapeutics to Participate in Upcoming Investor..
26/10/202323:01EDGAR2Form 8-K - Current report
26/10/202322:55EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
26/10/202322:30GLOBEMonte Rosa Therapeutics Announces $25 Million Registered..
17/10/202313:55EDGAR2Form 8-K - Current report
17/10/202313:00GLOBEMonte Rosa Therapeutics Announces Interim PK/PD and Clinical..
18/8/202322:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
15/8/202323:16EDGAR2Form 144 - Report of proposed sale of securities
10/8/202313:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202313:19EDGAR2Form 8-K - Current report
10/8/202313:15GLOBEMonte Rosa Therapeutics Announces Second Quarter 2023..
26/7/202313:53EDGAR2Form 8-K - Current report
26/7/202313:30GLOBEMonte Rosa Therapeutics Appoints Dr. Anthony M. Manning to..
30/5/202322:30GLOBEMonte Rosa Therapeutics to Present at Upcoming Investor and..
23/5/202313:30GLOBEMonte Rosa Therapeutics Advances Second Development..
11/5/202313:30GLOBEMonte Rosa Therapeutics Announces First Quarter 2023..
Apertura: 5,82 Min: 5,645 Max: 5,85
Chiusura: 5,60

La tua Cronologia

NASDAQ
GLUE
Monte Rosa Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network